The genetic basis and mode of inheritance of Usher syndrome are not certified in this packet. The packet distinguishes several subtypes, but it does not supply gene, mechanism, or inheritance information for any of them.

Diagnostic methods, diagnostic criteria, and newborn-screening information are not certified in this packet. The condition is defined by the combination of sensorineural deafness with retinitis pigmentosa and progressive vision loss.

The packet does not list approved treatments or management guidance for Usher syndrome. Orphan drug designation records are present for two investigational agents: a dual adeno-associated viral vector and a small-molecule compound, each designated for the treatment of Usher syndrome. A designation is a regulatory status granted during development and does not indicate marketing approval. Investigational studies are described under research.

Prognosis is not certified in this packet. The condition definition describes vision loss as progressive.

Certified active trial records are present for this condition. Examples include NCT07710196, a phase 3 trial of NPI-001 for the preservation of photoreceptors in retinitis pigmentosa associated with Usher syndrome (recruiting); NCT06789445, a phase 1 safety study of OpCT-001 in adults with primary photoreceptor disease (recruiting); and NCT05537220, a phase 3 study of oral N-acetylcysteine for retinitis pigmentosa (active, not recruiting). Active clinical trials for this condition are listed on ClinicalTrials.gov.